Precigen amends exclusive license agreement with Alaunos to bolster portfolio and broaden strategic opportunities –
– The Company also regains exclusive rights to IL-12 gene therapy, including application through the AdenoVerse™ platform– Agreement eliminates all future royalties to Alaunos –
– Precigen to host business and clinical update call on Tuesday, April 4, 2023 at 8:30 AM ET –
The Company will host a conference call on Tuesday, April 4, 2023 at 8:30 AM ET to provide business and clinical updates related to recent announcements. The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the participant access code 0835947. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Event details can be found on Precigen's website in the Events & Presentations section.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.